Mar 22, 2013 by Brian Orelli, PhDWhy Investors Shouldn't Jump on ACADIA's BandwagonACADIA jumps on the full presentation of pimavanserin data.
Mar 22, 2013 by Brian Orelli, PhD and Max MacalusoIs This the Next Investing Bubble?The Nasdaq Biotechnology Index recently hit a record high. Does that mean that biotech investors are in a bubble?
Mar 20, 2013 by Brian Orelli, PhDOrphan Drug Is Headed Back to Its ParentNPS reacquires rights to Revestive from Takeda.
Mar 18, 2013 by Brian Orelli, PhDAstraZeneca Reorganizes, Cutting 1,600 JobsConcentrating R&D to three sites part of reorganization thaht will result in one-time restructuring charges of $1.4 billion.
Mar 15, 2013 by Brian Orelli, PhDWhat Is This CEO Doing to Earn $450 Per Hour?Geron's CEO gets called out on an analyst call.
Mar 15, 2013 by Brian Orelli, PhDThis Drug Needs a Wake-Up CallUnder review since 2008, Merck will have to wait a little longer to see FDA approval of Bridion.
Mar 14, 2013 by Brian Orelli, PhDPick Your Poison: Diabetes or Pancreatic CancerThe FDA warns about diabetes drugs potentially increasing the rate of pancreatic cancer.
Mar 14, 2013 by Brian Orelli, PhDTick Tock Goes the Obesity ClockInvestors are waiting for a cardiovascular study from Orexigen.
Mar 13, 2013 by Brian Orelli, PhD and Max MacalusoWhat's Behind MannKind's Incredible Run?The biotech is on fire without any news.
Mar 13, 2013 by Brian Orelli, PhDDown 12%: Navidea's Post-Approval PlungeNavidea gets FDA approval but shares sink.
Mar 13, 2013 by Brian Orelli, PhDDown 35%! This Is a Biotech TrainwreckSpectrum guides for much lower Fusilev sales, causing shares to tank.
Mar 12, 2013 by Brian Orelli, PhDInvestors Must Wait to See if Merck Can Improve-ItMerck's trial testing cholesterol-lowering drug Vytorin continues.
Mar 11, 2013 by Brian Orelli, PhDIs Bristol-Myers Squibb One of the Best Companies in America?The drugmaker just missed the Fool's list of The 25 Best Companies in America.
Mar 11, 2013 by Brian Orelli, PhDIs Edwards Lifesciences One of the Best Companies in America?The medical device maker is on a tear but fails to make the Fool's list of The 25 Best Companies in America.
Mar 11, 2013 by Brian Orelli, PhDIs Merck One of the Best Companies in America?The pharma giant just missed the Fool's list of the Top 25 Companies in America.
Mar 11, 2013 by Brian Orelli, PhDDOJ Investigating Sanofi Over Plavix DisclosureThe French drugmaker says it learned of the federal investigation last year and is cooperating with investigators.
Mar 8, 2013 by Brian Orelli, PhD and Max MacalusoThe Obesity Drug War ContinuesFool analysts sit down to discuss the obesity drug market.
Mar 6, 2013 by Brian Orelli, PhDThe FDA Gift That Keeps On GivingBayer and J&J get another complete response letter from the FDA for Xarelto.
Mar 5, 2013 by Brian Orelli, PhD and Max MacalusoAnalyst Roundtable: Any Surprises in Amarin's Fourth Quarter?Motley Fool health care analyst Max Macaluso and Fool contributor Brian Orelli sit down to discuss Amarin.
Mar 5, 2013 by Brian Orelli, PhDThe Perfect Cure for Hepatitis C?Gilead's sofosbuvir and J&J's simeprevir produce outstanding data, but Gilead might take its ball and go home.
